Homœopathic Links 2019; 32(03): 174-180
DOI: 10.1055/s-0039-3400248
Proving
Thieme Medical and Scientific Publishers Private Ltd.

Asclepias curassavica—A Multicentric, Randomised, Double-Blind Homoeopathic Pathogenetic Trial

Rajpal Rajpal
1  Central Council for Research in Homoeopathy, New Delhi, India
,
Vinay Kr. Singh
1  Central Council for Research in Homoeopathy, New Delhi, India
,
V.A. Siddiqui
1  Central Council for Research in Homoeopathy, New Delhi, India
,
C. Nayak
1  Central Council for Research in Homoeopathy, New Delhi, India
,
A.K. Majumder
2  Drug Proving Research Unit (H), Kolkata, West Bengal, India
,
D.B. Sarkar
3  Drug Proving Research Unit (H), Midnapore, West Bengal, India
,
P.S. Sivadas
4  Central Research Institute (H), Kottayam, Kerala, India
,
K. Banoth
5  Regional Research Institute (H), Gudivada, Andhra Pradesh, India
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2019 (online)

Abstract

Objective To elicit the pathogenetic response of the drug Asclepias curassavica in homoeopathic potencies on healthy human beings.

Methodology Drug Asclepias curassavica was proved by the Central Council for Research in Homoeopathy through randomised, double-blind, placebo-controlled method. The study was conducted at four centres. The drug was proved in two potencies (6C and 30C) on 67 apparently healthy volunteers who were selected after conducting pre-trial medical examination by the medical specialists and routine laboratory investigations. In the first phase, volunteers were given 56 doses (04 doses per day for 14 days) of placebo. In the next two phases, 56 doses (04 doses per day for 14 days) of each potency or placebo were consumed. The symptoms generated during the trial period were noted by the volunteers and elaborated by the Proving Masters. The data obtained from all the four centres was compiled at proving-cum-data processing cell at CCRH headquarters after de-coding.

Observations Out of the 44 provers who were on actual drug trial, 21 manifested symptoms. Drug was able to produce symptoms in both the potencies more or less related to every part of the body.

Conclusion The pathogenetic responses elicited during the proving trial expands the scope of use of the drug Asclepias curassavica and will benefit the research scholars and clinicians. These symptoms will carry more value when verified clinically.

Reprinted with permission from: Asclepias currasavica - A multicentric, randomized, double-blind Homoeopathic Pathogenetic Trial. Indian J Res Homoeopathy 2011;5(3):6–14.